Femasys Q1 Revenues Climb 24.5% to $424.9K, Posts $846K Profit
Femasys reported a 24.5% revenue rise to $424,889 and swung to net income of $846,100 in Q1 2026, compared with a $5.9 million loss year-ago. Cash stood at $5.4 million, funding operations into Q3, as the company advanced FemaSeed and FemBloc commercial launches and pivotal trial enrollment.
1. Corporate and Commercial Progress
During Q1 2026 Femasys expanded FemaSeed Complete adoption by OB/GYNs, launched at ACOG 2026, and secured new distribution partnerships in Israel and Switzerland. The company initiated patient enrollment in the FINALE pivotal trial for its non-surgical FemBloc birth control, achieved MDSAP certification, and obtained a Category III CPT code for FemaSeed intratubal insemination, supporting reimbursement and broader market access.
2. Financial Performance
Sales rose by $83,625, or 24.5%, to $424,889, driven primarily by FemBloc product sales, while research and development expenses fell by $1.66 million, or 55.9%, to $1.31 million. Femasys reported net income of $846,100, reversing a $5.9 million loss a year earlier, and ended the quarter with an accumulated deficit of $145 million.
3. Outlook and Cash Runway
With $5.4 million in cash and equivalents, Femasys expects to fund operations into the third quarter of 2026 and remains focused on scaling its women’s health portfolio globally. Leadership additions, including a new COO and board member, aim to support operational execution and commercial growth through the next phases of product rollout and regulatory milestones.